Erica Mulcaire-Jones
Rheumatology · Ann Arbor, MINPI 1437577541
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $718 of the $1,169 with a category attached, or 61.4%. AstraZeneca accounts for 84.9% of it on its own, with 2 other manufacturers making up the rest. That places this record below the midpoint for rheumatology clinicians in MI, where the typical reported total is $1,854.
Across 13 payments — averaging $89.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$992
- Novartis$130
- Boehringer Ingelheim$47
Across 44 payments — averaging $11,154 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$201K
- Boehringer Ingelheim International GmbH$144K
- GSK$86K
- Argenx US, Inc.$40K
- Tanabe Pharma America, Inc.$19K
What the payments were for
- Travel & lodging$71861%
- Food & beverage$45139%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 11 | $992 |
| Novartis | 1 | $130 |
| Boehringer Ingelheim | 1 | $47 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SAPHNELO$718
How this compares
$1,169 in reported general payments places this provider in the 40th percentile of 195 rheumatology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Actemra ActpenTocilizumab | 41 | $196,707 |
| Humira(Cf) PenAdalimumab | 25 | $187,255 |
| Enbrel SureclickEtanercept | 24 | $179,174 |
| SimponiGolimumab | 29 | $173,208 |
| KineretAnakinra | 27 | $149,029 |
| Orencia ClickjectAbatacept | 20 | $119,703 |
| EnbrelEtanercept | 14 | $102,889 |
| ActemraTocilizumab | 16 | $72,558 |
| OrenciaAbatacept | 12 | $60,880 |
| XeljanzTofacitinib Citrate | 11 | $60,487 |
| Mycophenolate Mofetil | 106 | $28,527 |
| Sildenafil Citrate | 46 | $7,192 |
| Hydroxychloroquine Sulfate | 86 | $6,323 |
| MethotrexateMethotrexate Sodium | 120 | $5,771 |
| Mycophenolic AcidMycophenolate Sodium | 19 | $4,544 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Ann Arbor
- Dinesh KhannaAnn Arbor$1.2M
- Elena SchiopuAnn Arbor$180K
- Daniel ClauwAnn Arbor$102K
- Katherine ChakrabartiAnn Arbor$82K
- Puja KhannaAnn Arbor$78K
- Joanne KahlenbergAnn Arbor$74K
- John VargaAnn Arbor$64K
- Samardeep GuptaAnn Arbor$58K
- Jason KnightAnn Arbor$38K
- Sheeja FrancisAnn Arbor$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.